Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Friday. $269.87 million flowed into the stock on the tick-up and $106.26 million flowed out of the stock on the tick-down, for a money net flow of $163.61 million into the stock. Of all stocks tracked, Pfizer had the 8th highest net in-flow for the day. Pfizer traded down ($0.15) for the day and closed at $36.77

A number of brokerages have recently commented on PFE. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $37.97 price objective for the company. in a research report on Thursday. Jefferies Group set a $41.50 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday. Piper Jaffray Cos. reissued an “overweight” rating and set a $54.00 target price on shares of Pfizer in a research note on Monday, June 27th. Deutsche Bank AG reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, June 15th. Finally, TheStreet raised shares of Pfizer from a “hold” rating to a “strong-buy” rating in a research note on Friday, June 3rd. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $38.11.

The firm’s 50 day moving average is $35.15 and its 200-day moving average is $32.24. The company has a market capitalization of $223.00 billion and a price-to-earnings ratio of 30.14.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.12. During the same quarter in the previous year, the business earned $0.51 earnings per share. The company had revenue of $13 billion for the quarter, compared to analyst estimates of $12 billion. The company’s revenue was up 19.3% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post $2.44 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Friday, August 5th will be issued a dividend of $0.30 per share. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.26%.

In other Pfizer news, EVP Laurie J. Olson sold 4,700 shares of Pfizer stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $33.50, for a total value of $157,450.00. Following the sale, the executive vice president now directly owns 71,659 shares in the company, valued at approximately $2,400,576.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Frank A. Damelio sold 100,000 shares of Pfizer stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $34.49, for a total transaction of $3,449,000.00. Following the completion of the sale, the executive vice president now owns 472,994 shares in the company, valued at $16,313,563.06. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. San Francisco Sentry Investment Group CA raised its stake in shares of Pfizer by 0.4% in the fourth quarter. San Francisco Sentry Investment Group CA now owns 32,934 shares of the biopharmaceutical company’s stock valued at $1,063,000 after buying an additional 125 shares during the last quarter. Sheets Smith Wealth Management raised its stake in shares of Pfizer by 1.3% in the fourth quarter. Sheets Smith Wealth Management now owns 33,001 shares of the biopharmaceutical company’s stock valued at $1,065,000 after buying an additional 436 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of Pfizer by 4.8% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 33,248 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 1,524 shares during the last quarter. Mycio Wealth Partners LLC raised its stake in shares of Pfizer by 5.8% in the fourth quarter. Mycio Wealth Partners LLC now owns 33,436 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 1,825 shares during the last quarter. Finally, Cobblestone Capital Advisors LLC NY raised its stake in shares of Pfizer by 12.1% in the fourth quarter. Cobblestone Capital Advisors LLC NY now owns 34,231 shares of the biopharmaceutical company’s stock valued at $1,105,000 after buying an additional 3,700 shares during the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.